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Background: Lupus nephritis (LN) affects up to 80% of juvenile-onset systemic lupus erythe-
matosus (JSLE) patients. The value of commonly available biomarkers, such as anti-dsDNA
antibodies, complement (C3/C4), ESR and full blood count parameters in the identification of
active LN remains uncertain. Methods: Participants from the UK JSLE Cohort Study, aged
<16 years at diagnosis, were categorized as having active or inactive LN according to the renal
domain of the British Isles Lupus Assessment Group score. Classic biomarkers: anti-dsDNA,
C3, C4, ESR, CRP, haemoglobin, total white cells, neutrophils, lymphocytes, platelets and
immunoglobulins were assessed for their ability to identify active LN using binary logistic
regression modeling, with stepAIC function applied to select a final model. Receiver-operating
curve analysis was used to assess diagnostic accuracy. Results: A total of 370 patients were
recruited; 191 (52%) had active LN and 179 (48%) had inactive LN. Binary logistic regression
modeling demonstrated a combination of ESR, C3, white cell count, neutrophils, lymphocytes
and IgG to be best for the identification of active LN (area under the curve
0.724). Conclusions: At best, combining common classic blood biomarkers of lupus activity
using multivariate analysis provides a ‘fair’ ability to identify active LN. Urine biomarkers
were not included in these analyses. These results add to the concern that classic blood
biomarkers are limited in monitoring discrete JSLE manifestations such as LN. Lupus
(2017) 0, 1–6.
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Introduction
Juvenile-onset systemic lupus erythematosus
(JSLE) is a heterogeneous life-threatening multi-
system autoimmune disease, exhibiting a more
aggressive course when onset is in childhood.1
The value of commonly available classic bio-
markers of overall JSLE activity in identifying dis-
crete aspects of JSLE, such as lupus nephritis (LN),
remains uncertain. LN is more common in JSLE
than in adult counterparts, with up to 80% of
JSLE patients having some renal involvement
within a 5-year period.2 Renal histology is the
gold standard for LN identiﬁcation, but is seldom
repeated serially due to its invasive nature. Eﬀective
treatment of LN relies on early recognition of the
often subtle presenting features, to prevent renal
damage.
Clinicians rely heavily on non-invasive markers
such as proteinuria, serum creatinine and glomeru-
lar ﬁltration rate (GFR) when monitoring JSLE
patients. Following a LN ﬂare, proteinuria has
been shown to take a signiﬁcant period of time to
normalize, with 53% of adult LN patients requiring
up to 2 years to recover and 74% recovering by 5
years.3 During this time, diﬀerentiating between
proteinuria due to irreversible damage of the glom-
erular capillaries or a LN ﬂare is problematic, limit-
ing the reliability of proteinuria in ongoing
monitoring. Spot albumin or protein creatinine
ratio measurements are largely used as an alterna-
tive to 24-hour urinary protein quantiﬁcation; how-
ever, the correlation between spot protein/
creatinine ratio and 24-hour urine protein has
recently been shown to be poor in those with a
high or medium LN activity index score.4
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There have also been numerous reports of clin-
ically silent LN in patients with biopsy deﬁned LN
but no proteinuria, normal urinalysis and normal
renal function.5 The best calculation for GFR
measurement in LN patients has been shown to
be the Cockcroft–Gault equation using ideal body
weight in the calculation. Deviation from this
approach as part of the standard protocols used
in some institutions may also inﬂuence the reliabil-
ity of GFR measurements in systemic lupus erythe-
matosus (SLE) patients.6
The above studies highlight uncertainties relating
to conventional renal function measurements in
SLE. Studies looking at the role of other routinely
measured immunological, haematological and
inﬂammatory biomarkers in active LN identiﬁca-
tion have mainly focused on adult patients. The
aim of this study was therefore to use participants
from the UK JSLE Cohort Study2 to assess the
ability of classic biomarkers of JSLE for identiﬁca-




Children participating in the UK JSLE Cohort
Study2 between 2005 and 2015, aged under 16
years at the time of diagnosis, meeting four of
more of the American College of Rheumatology
(ACR) SLE classiﬁcation criteria were recruited.
Disease activity and classic biomarker data were
collected using the paediatric British Isles Lupus
Assessment Group (BILAG; pBILAG2004) disease
activity score.7 Written patient assent/consent and
parental consent was obtained, and the study had
full ethical approvals in place from the National
Research Ethics Service North West, Liverpool
East (REC reference 06/Q1502/77). The research
was carried out in accordance with the
Declaration of Helsinki.
Patient groups
Patients were categorized according to the renal
domain of pBILAG2004 disease activity score,
deﬁned as follows: pBILAG2004 grade A/B:
severe, moderate renal disease respectively; grade
C: mild renal disease; grade D: inactive disease
but previous renal system involvement; grade E:
renal system has never been involved. The compos-
ite renal domain of the BILAG score consists of six
items including renal function (deterioration based
on serum creatinine and GFR), proteinuria
(deﬁned by urine dipstick, or urine protein/albumin
creatinine ratio (UPCR/UACR), or 24 hour
protein levels), nephrotic syndrome, active urinary
sediment, hypertension and histological evidence of
active nephritis in the previous 3 months. Diﬀerent
cut-oﬀs for the above clinical investigations corres-
pond to the diﬀerent renal BILAG disease activity
categories.7 Patients were then grouped as follows:
. Active LN: if they had a renal pBILAG2004 of
A or B.
. Inactive LN: if they had a renal pBILAG2004 of
D or E.
Patients who were graded ‘C’ were excluded
from analysis. The study was undertaken on a
cross-sectional basis. Individual patient visits were
selected when the clinical data were most complete.
Classic blood biomarkers investigated
Anti-dsDNA, C3, C4, ESR, CRP, haemoglobin,
total white cell count (WCC), neutrophils, lympho-
cytes, platelets and immunoglobulin (IgG, IgA,
IgM) levels were compared between patients with
active and inactive LN. As our deﬁnition of active
LN was based on the composite renal BILAG
score, calculated from proteinuria, GFR, blood
pressure, active urine sediment, plasma creatinine
and recent biopsy ﬁndings, we could not investigate
the performance of these classic renal biomarkers.
Statistical analysis
Demographic and classic biomarker data were not
normally distributed and therefore were expressed
as median values and interquartile ranges (IQR).
Mann–Whitney U tests were used to compare the
distribution of the classic biomarker levels
between active and inactive LN patients
(Bonferroni correction method applied to account
for multiple testing, 17 comparisons). A binary
logistic multiple regression model was ﬁtted to
assess for association between a combination of
classic biomarkers and LN status (outcome: LN
active 1; non-LN JSLE 0). All classic biomarkers
(log-transformed) excluding those contributing to
the renal BILAG score (UACR, UPCR, GFR,
plasma creatinine) were included in an initial
model and the ‘stepAIC’ function in R8 applied
to select a ﬁnal model. This function compares
diﬀerent models based on all possible combin-
ations of biomarkers and chooses the model with
the minimum Akaike information criterion (AIC)
value. The AIC is a measure of the relative quality
of a model relative to each of the other models,
with a lower value representing better quality. The
area under the curve (AUC) for the ﬁnal model
was calculated. AUC values of 1.0–0.9, 0.9–0.8,
0.8–0.7, 0.7–0.6 and 0.6–0.5 were considered
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‘excellent, good, fair, poor and fail’, respectively.
Data analysis and was undertaken using R version
3.1.1.8 Where Bonferroni adjustment was made to
account for multiple testing, the Bonferroni cor-
rected P value, Pc is reported.
Results
Patient demographics
The study cohort consisted of 370 JSLE patients,
191 active LN patients and 179 inactive, with a
median age of 12.7 and 12.8 years, respectively, at
diagnosis (Table 1). All patients fulﬁlled at least
four ACR classiﬁcation criteria at diagnosis. At
the time of analysis, disease duration for active
and inactive LN patients was 0.5 and 0.6 years,
respectively. The female to male gender ratio was
5.0:1 for active LN patients and 4.8:1 for inactive
LN patients. The most commonly self-reported
patient ethnicity in both groups was Caucasian
(54% active group and 51% inactive group), fol-
lowed by Indian, Pakistani or Bangaldeshi (21%
active group and 21% inactive group). No statistic-
ally signiﬁcant diﬀerences were observed on com-
paring any of the reported demographics between
the active and inactive groups (Pc> 0.05 for all, see
Table 1).
Individual classic biomarkers
Table 2 summarizes the median and interquartile
ranges for renal and non-renal classic biomarker
concentrations in the active and inactive LN
patient groups separately. Univariate analysis of
the association between each classic biomarker
and LN status revealed a statistically signiﬁcant
diﬀerence in concentration of C3, C4, ESR, haemo-
globin, UACR and UPCR between patients with
active LN and those with inactive LN (all
Pc< 0.05). The concentration of serum creatinine,
anti-dsDNA, neutrophils, eGFR, CRP, WCC,
lymphocyte/platelet counts and IgG, IgA and
IgM did not diﬀer between patient groups (all
Pc> 0.05).
Strength of non-renal classic biomarkers in
combination for identifying active LN
A binary multiple logistic regression model was
ﬁtted including all classic biomarkers which do
not contribute to the renal BILAG score, and
then applying the R ‘StepAIC’ function.8
The ﬁnal selected model included six classic bio-
markers including ESR, C3, WCC, neutrophils,
lymphocytes and IgG (see Table 3). The AUC
corresponding to this ﬁnal model was 0.724,
demonstrating this optimal combination of classic




(n¼ 191)a Pc valueb
Age at diagnosis (years) 12.7 (10.1–14.3) 12.8 (10.8–14.5) 1.000
Disease duration (years) 0.6 (0–1.7) 0.5 (0–2.6) 1.000
Gender (F:M ratio) 4.8:1 5:1 1.000
ACR criteria at diagnosis 4 (4–5) 5 (4–5) 1.000
Patient ethnicity (n, %)c
 Caucasian 95 (54%) 95 (51%)
 African 12 (6%) 12 (6%)
 Caribbean 6 (3%) 10 (5%)
 Mixed race 14 (8%) 14 (7%) 0.717
 Indian/Pakistani/
Bangladeshi
38 (21%) 40 (21%)
 Chinese 3 (2%) 8 (4%)
 Other Asian 11 (6%) 12 (6%)
aResults expressed as median values and interquartile ranges. Chi
squared and Mann–Whitney U tests used to assess for differences in
demographic/clinical factors between different patient groups as
appropriate.
bP valuec: Bonferroni-corrected P values.
cEthnicity data are patient reported.
JSLE: juvenile-onset systemic lupus erythematosus; LN: lupus neph-
ritis; F:female; M: male; ACR: American College of Rheumatology.
Table 2 Classic biomarker measurements in active versus
inactive LN patients
na Inactive LNb Active LNb Pc value
c
Anti-dsDNA (IU/L) 308 29 (7–154) 77 (13–261) 0.068
C3 (g/L) 339 0.99 (0.75–1.23) 0.78 (0.43–1.08) <0.001
C4 (g/L) 338 0.15 (0.08–0.20) 0.10 (0.05–0.19) 0.017
ESR (mm/h) 327 18 (6–40) 40 (11–80) <0.001
CRP (mg/L) 306 5 (3–7) 5 (3–7) 1.000
Haemoglobin (g/dl) 367 12.1 (10.8–13.2) 11.5 (9.9–12.8) 0.014
White cells (109/L) 365 5.4 (4.2–7.1) 5.7 (4.0–8.8) 1.000
Neutrophils (109/L) 365 3.2 (2.1–4.3) 3.6 (2.4–6.4) 0.053
Lymphocytes (109/L) 365 1.3 (0.9–1.9) 1.3 (0.9–1.9) 1.000
Platelets (109/L) 364 270 (207–325) 261 (196–335) 1.000
IgG (g/L) 291 13.7 (10.9–18.6) 12.0 (9.2–18.1) 1.000
IgA (g/L) 289 1.8 (1.2–2.4) 1.9 (1.2–2.8) 1.000
IgM (g/L) 287 1.2 (0.8–1.7) 1.0 (0.6–1.6) 1.000
UACR (mg/mmol Cr) 130 0.9 (0.5–2.2) 23.9 (2.5–109.7) <0.001
UPCR (mg/mmol Cr) 141 11 (5–15) 102 (60–325) <0.001
eGFR (ml/min/m2) 267 116 (99–130) 108 (87–108) 1.000
Serum creatinine (mmol/L) 318 54 (46–54) 61 (48–57) 1.000
aNumber of patients contributing to analysis for each laboratory
parameter.
bExpressed as median values and interquartile ranges.
cP valuec: Bonferroni-corrected P values.
LN: lupus nephritis; UACR: urinary albumin to creatinine ratio;
UPCR: urinary protein creatinine ratio; eGFR: estimated glomerular
filtration rate.
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non-renal biomarkers to have ‘fair’ ability for
active LN identiﬁcation.
Discussion
Using a cross-sectional national cohort of paediat-
ric patients recruited to the UK JSLE Cohort
Study, the aim of this study was to assess the ability
of classic immunological and haematological bio-
markers of JSLE to identify active LN compared to
inactive LN, both individually and in combination.
Previous studies have largely focused on individual
biomarkers and adult-onset SLE populations.
This study univariately showed ESR, C3, C4,
haemoglobin, UACR and UPCR to diﬀer signiﬁ-
cantly between active and inactive LN patients (all
Pc< 0.05). When all classic biomarkers which do
not contribute to the renal BILAG score were con-
sidered within a binary multiple logistic regression
model, ESR, C3, WCC, neutrophils, lymphocytes
and IgG were shown to contribute signiﬁcantly to
the optimal model for the identiﬁcation of active
LN. The accuracy of these tests for identifying
active LN was assessed using area under the recei-
ver operating characteristic curve analysis, with the
area measuring discrimination, i.e. the ability of the
test to classify correctly those with and without LN.
AUC values of 1.0–0.9, 0.9–0.8, 0.8–0.7, 0.7–0.6
and 0.6–0.5 correspond to a test being ‘excellent,
good, fair, poor and failing’. Although ESR, C3,
WCC, neutrophils, lymphocytes and IgG levels dif-
fered signiﬁcantly, their accuracy as a test for active
LN fell in the ‘fair’ range when considered in com-
bination (AUC 0.724).
These results complement those of an adult-
onset SLE study which showed decreases in C3 to
be associated with renal disease activity, despite
inconsistent performance for predicting global
SLE activity.9 In a prospective study serially moni-
toring C3/C4 levels in adult SLE patients, C4 was
demonstrated to deteriorate before C3, starting 25
and 20 weeks, respectively, before the LN ﬂare
becoming clinically detectable.10 Together with
anti-dsDNA antibody levels, C3/C4 levels have
been shown to have a good negative predictive
value for active LN in a 6-year prospective study
of 228 LN patients.11 Complement fragments C3d-
CIC and C5a have previously been shown to be
signiﬁcantly higher in active compared to inactive
JSLE patients,12 but these data are not collected by
the UK JSLE Cohort Study, and therefore could
not be included in these analyses.
Our ﬁndings relating to ESR are also in keeping
with those of a recent adult SLE study that showed
ESR to be correlated with renal involvement and
fatigue according to the lupus activity index visual
analogue scales (VAS), the overall safety of estrogen
in lupus national assessment–systemic lupus erythe-
matosus disease activity index (SELENA–SLEDAI)
score and physician global assessment (PGA). ESR
was also correlated with haematuria and proteinuria
during the current visit. Over time, a change in ESR
between two visits was highly correlated with a con-
current change in the PGA and renal VAS but not
changes in overall disease activity.13 ESR is clearly
an easily accessible and inexpensive test, which has
some utility in monitoring renal and global disease
activity but is very non-speciﬁc in separating renal
and global disease activity.
Anti-dsDNA antibody levels did not feature in
the ﬁnal multiple logistic regression model. Similar
results have previously been reported in a study
assessing anti-dsDNA antibody and C3/C4 levels,
in 53 adult SLE patients 3–9 months preceding a
ﬂare. For all three tests, sensitivity and speciﬁcity
for predicting renal and non-renal ﬂares was in the
region of 50% and 75%, respectively, with positive
and negative likelihood ratios being close to 1.0,
suggesting little clinical value as a routine test.14
In contrast, high titres of anti-dsDNA have been
shown to diﬀerentiate proliferative from non-pro-
liferative LN at the time of renal biopsy,15 with
some studies concluding that increased anti-
dsDNA antibody levels should prompt preemptive
treatment due to the strong ability of anti-dsDNA
to predict SLE ﬂares.16 These conﬂicting results
may be due to diﬀerences in sample size, disease
activity measures and the frequency of biomarker
testing.
Table 3 Binary logistic regression model for identification of
active LN using classic biomarkers
Final model fitted by including all biomarkers in a
multiple logistic regression model and applying
‘StepAIC’ function
Biomarkers Coefficient Standard Error P value AUC
ESR 0.019 0.007 0.003 0.724
C3 –1.035 0.488 0.034
White cells –0.699 0.423 0.098
Neutrophils 0.795 0.427 0.06
Lymphocytes 0.735 0.503 0.144
IgG –0.061 0.026 0.017
StepAIC function: step Akaike Information Criterion function, 185
patients (88 active lupus nephritis (LN) and 97 inactive LN) included
in this model as patients excluded when classic biomarker measure-
ments were missing.
AUC: area under the curve.
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This study is the largest to date in children and
young people with JSLE looking at the perform-
ance of classic biomarkers for LN identiﬁcation.
We recognize that there are certain limitations to
this work, which should be addressed in future stu-
dies. In this study we were interested in the per-
formance of biomarkers not considered of classic
renal origin (e.g. anti-dsDNA antibodies, C3/C4,
ESR, full blood count parameters, etc.) as our def-
inition of active LN was based on the composite
renal BILAG score (calculated from proteinuria,
blood pressure, serum creatinine, GFR, active
urine sediment and recent biopsy ﬁndings). To
look more closely at all classic biomarkers available
to the clinician, including those involved in calcu-
lation of the composite renal BILAG score, further
large prospective longitudinal studies are warranted
using diﬀerent outcome measures (e.g. renal biopsy
deﬁned LN). Such future analysis would indicate
the diagnostic value of the full range of urine and
blood tests which are available to the clinician. It
would also be of interest to explore the eﬀect of
combining classic blood and urine biomarkers
with novel urine biomarkers, as such novel bio-
markers have been shown to be extremely useful
in the identiﬁcation of active LN.17
Patient episodes in which a renal BILAG score
of C was scored were not included in this current
study. Renal BILAG C patients can be a rather
heterogeneous group of patients with mild LN
(scoring a C on the basis of a urine dipstick value
of 1þ) or with slowly improving renal disease in
which the urine protein–creatinine ratio can still in
fact be very high, but can have improved by 25% or
greater in the previous 4 weeks. The renal BILAG
score has been shown to be most sensitive for the
detection of new-onset LN and a signiﬁcant
improvement of renal disease activity;18 therefore,
this current study included a more dichotomous
group of patients with clearly deﬁned active
versus inactive LN (renal BILAG A/B vs. D/E).
Such a renal BILAG score deﬁnition of active LN
has previously been utilized within a large number
of studies looking at the ability of urine and serum
biomarkers to diﬀerentiate active and inactive
LN.19–23 A further analysis of the role of classic
biomarkers in renal BILAG C patients would be
of interest.
Conclusions
JSLE patients have signiﬁcant renal involvement
and the potential to develop irreversible renal
damage as a result of unrecognized LN relapses.
At best, combining ESR, C3, WCC, neutrophils,
lymphocytes and IgG provided a ‘fair’ ability to
identify active LN. In contrast, novel urine bio-
markers have been shown to be ‘excellent’ for iden-
tifying active LN (AUC up to 0.92), in the UK
JSLE Study Cohort.17 In the future, to optimize
the eﬀective management of LN, easily measured
novel biomarkers are anticipated to add to the
information gained from classic biomarkers.
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